by Madeleine Hubbard
Pharmaceutical manufacturer Eli Lilly and Company on Wednesday announced it would reduce the price of its most commonly prescribed insulins by 70% and expand its Insulin Value Program that limits patients’ monthly out-of-pocket costs to $35 or less.
“While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change,” Lilly CEO David Ricks said.
“We are driving for change in repricing older insulins, but we know that 7 out of 10 Americans don’t use Lilly insulin,” Ricks also said. “We are calling on policymakers, employers and others to join us in making insulin more affordable.”
Lilly’s announcement comes after a provision in the Inflation Reduction Act reduced insulin costs to $35 a month for Medicare enrollees starting this year.
– – –
Madeleine Hubbard joined Just the News as a fast file reporter after working as an editor at Breitbart News. Hubbard previously served as the special assistant to the Assistant Secretary of Public Affairs at the U.S. Department of Health and Human Services during the first year of the COVID-19 pandemic.
Photo “Eli Lilly Research Scientist” by Eli Lilly.
